Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 5/20 | 0.34 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14474684 | 0.93 | CHRNA7 (0.39) | CHRNA7NPC1RAB9ALIMK1MAPK14 | |
| SCHEMBL16184198 | 0.91 | TGFBR1 (0.38) | NPC1RAB9AMAP3K11TGFBR1LMNA | |
| SCHEMBL14475264 | 0.90 | PIM1 (0.36) | CHRNA7LIMK1MAPK14GRM5LMNA | |
| SCHEMBL14474202 | 0.90 | CHRNA7 (0.45) | CHRNA7LIMK1MAPK14GRM5MAP3K11 | |
| SCHEMBL16184367 | 0.89 | NPC1 (0.39) | CHRNA7NPC1RAB9ACASP6TGFBR1 | |
| SCHEMBL16185154 | 0.88 | GRM5 (0.42) | CHRNA7MAPK14GRM5LMNA | |
| SCHEMBL16185156 | 0.87 | CHRNA7 (0.38) | CHRNA7GRM5MAP3K11CASP6NAMPT | |
| SCHEMBL16184847 | 0.87 | CYP1A2 (0.43) | CHRNA7NPC1GRM5POLBMAPT | |
| SCHEMBL16185160 | 0.87 | GRM5 (0.40) | CHRNA7GRM5MAP3K11POLBLMNA | |
| SCHEMBL16185168 | 0.87 | CHRNA7 (0.37) | CHRNA7LIMK1MAPK14GRM5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | CHRNA7 349/4885NPC1 2208/4885RAB9A 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.